News articles about Hospira (NYSE:HSP) have been trending somewhat negative recently, according to Accern. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Hospira earned a media sentiment score of -0.05 on Accern’s scale. Accern also assigned news coverage about the healthcare company an impact score of 71 out of 100, indicating that recent news coverage is likely to have an impact on the company’s share price in the immediate future.

TRADEMARK VIOLATION WARNING: This piece was published by Daily Political and is the property of of Daily Political. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at

About Hospira

Hospira, Inc provides injectable pharmaceutical drugs and infusion technologies and it develops, manufactures, distributes and markets biosimilars. The Company’s portfolio includes generic acute-care and oncology injectables, biosimilars, and integrated infusion therapy and medication management products.

Insider Buying and Selling by Quarter for Hospira (NYSE:HSP)

Receive News & Ratings for Hospira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hospira Inc. and related companies with's FREE daily email newsletter.